Longeveron (LGVN) Enterprise Value (2021 - 2026)
Longeveron (LGVN) recorded quarterly Enterprise Value of -$15.8 million in Q1 2026, down 238.08% quarter-over-quarter from -$4.7 million in Q4 2025, and down 9.99% on a YoY basis from -$17.5 million in Q1 2025.
Longeveron (LGVN) Enterprise Value (2021 - 2026) Analysis & Trends
Longeveron's Enterprise Value history runs 6 years deep, the most recent figure standing at -$15.8 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 9.99% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$15.8 million (down 9.99% YoY), while the FY2025 annual figure was -$4.7 million, up 75.76% from the prior year.
- Enterprise Value was -$15.8 million for Q1 2026 at Longeveron, down from -$4.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.3 million in Q1 2024 to a low of -$22.8 million in Q3 2024.
- Historically, Enterprise Value has averaged -$10.8 million across 5 years, with a median of -$9.8 million in 2025.
- Biggest YoY gain for Enterprise Value was 75.76% in 2025; the steepest drop was 525.36% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$19.7 million in 2022, then surged by 72.73% to -$5.4 million in 2023, then sank by 258.74% to -$19.2 million in 2024, then soared by 75.76% to -$4.7 million in 2025, then tumbled by 238.08% to -$15.8 million in 2026.
- The last three Enterprise Value figures came in at -$15.8 million (Q1 2026), -$4.7 million (Q4 2025), and -$9.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -4.66 Mn |
| Sep 30, 2025 | -9.20 Mn |
| Jun 30, 2025 | -10.33 Mn |
| Mar 31, 2025 | -14.33 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -22.80 Mn |
| Jun 30, 2024 | -12.38 Mn |
| Mar 31, 2024 | -2.29 Mn |
| Dec 31, 2023 | -5.36 Mn |
| Sep 30, 2023 | -3.93 Mn |
| Jun 30, 2023 | -8.66 Mn |
| Mar 31, 2023 | -2.30 Mn |
| Dec 31, 2022 | -19.66 Mn |
| Dec 31, 2021 | -35.04 Mn |